Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Berry Genomics to Reverse-Merger at a $619 Million Valuation

publication date: Dec 23, 2016
Berry Genomics, a Beijing genetic testing company, will IPO via a reverse merger with Chengdu Tianxing Instrument & Meter at a valuation of $619 million on China's Shenzhen market. The transaction was announced in September, but no financial details were disclosed at that time. Tianxing will issue shares to Berry stockholders. Earlier this month, Tianxing said it would sell its assets and debts for $42 million, though it wasn't clear if that was all of the company's current operations. More details....

Stock Symbol: (SHZ: 0710)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital